how different kind of fats are extracted from fecal homogenate and the effect of acidification on extraction efficiency. Our results provide additional evidence that fecal acidification improves fat extraction and precision. Tran et al. (6) reported an increase in acid steatocrit values ranging between 50% and 3364%, with a substantial improvement in fat extraction. They found that the amount of fat in the fatty layer was greater after acidification of the fecal sample and that acid steatocrit results agreed with chemically measured fecal fat better than the classic method did. Tran et al. (5) speculated that fecal acidification would lead to conversion of the ionized fatty acid species into protonated species, which would improve separation into lipid and water layers during the centrifugation step. This may occur to a greater extent for saturated fatty acids, as compared with unsaturated acids. Our data indicate that the type of fat present in the sample affects the extent to which acidification improves fat extraction from fecal homogenates. The importance of acidification was particularly evident for samples with added butter, which showed a major improvement of CVs, both for the within-day and the between-day precision assays when the acid steatocrit was performed. These findings seem to indicate that saturated fats of animal origin are more efficiently extracted when the fecal homogenate is acidified, and may explain the results obtained by Walters et al. (4) with the classic steatocrit in England.
We conclude that in vitro steatocrit values are influenced differently according to the type of fat present in the fecal homogenate. The steatocrit may thus be influenced by dietary composition, and its reference interval may vary according to differences in diet. The influence of dietary fat composition on steatocrit results may be more fully assessed in vivo through dietary modifications, but this approach may be difficult to achieve. Acidification may limit the clinical impact of these shortcomings by improving fat extraction from fecal homogenates. Autoantibodies to the thyrotropin (TSH) receptor (TSHR) are the hallmark of the autoimmune response to the thyroid gland and are responsible for thyrotoxicosis in Graves disease (1 ) . Unlike other autoantibodies, there is no direct assay for TSHR antibodies. Instead, these antibodies are detected either by their ability to inhibit binding of radiolabeled TSH to receptors or by a bioassay of TSHR activation (2, 3 ) . The most widely used assay is a radioreceptor assay, which uses solubilized porcine TSHR, in which the antibody is called TSH-binding inhibitory immunoglobulin (TBII). Serum TBII is easily assayed with a commercially available kit; however, 5-10% of patients with Graves disease show a negative reaction perhaps related to inadequacies of the assay (4 ). Addition of polyethylene glycol (PEG) enhances cAMP production induced by a patient's IgG, but not by TSH, forskolin, or GTP␥S in an in vitro bioassay for thyroid stimulators (5 ) , suggesting that the enhancement occurs at the step of antibody-receptor interaction. We recently found that the modification of TSHR with detergent changed the nature of the binding of TSHR to anti-TSHR antibodies (6 ) . On the basis of these findings, we examined whether the addition of PEG increase the ability of the TBII assay to detect autoantibodies to the TSHR.
Polyethylene Glycol Increases the Detection of Anti-Thyrotropin Receptor Antibodies by a Radioreceptor
The TBII assay was performed as described previously (4, 6 ) . Serum samples (50 L) were incubated in duplicate with solubilized porcine TSHR (50 L) for 15 min at room temperature (first incubation). 125 I-labeled bovine TSH (50 L) and assay buffer (100 L) were then added, and the incubation was continued for 60 min at 37°C (second incubation). Six hundred microliters of 300 g/L PEG (average M r 6000), 250 L of assay buffer, and 50 L of 500 g/L PEG were then added to the incubated mixture. The mixture was then centrifuged at 2000g for 20 min at 4°C, and the radioactivity in the pellets was measured. TBII activity was expressed as inhibition of labeled TSH binding (4 ) .
To examine the effect of PEG on TBII activity, 50 L of 500 g/L PEG, 50 L of 125 I-TSH, and 50 L of assay buffer were added to the mixture before the second incubation (final concentration of PEG was 100 g/L). After the mixture was incubated for 60 min at 37°C, 600 L of 300 g/L PEG and 300 L of assay buffer were added, the radioactive fraction was precipitated, and the radioactivity was measured.
In samples from 24 untreated patients with Graves disease and positive TBII (group A in Fig. 1 ), the TBII activity increased significantly (P Ͻ0.0001) after the addition of PEG. We next examined 17 untreated patients with Graves disease and negative TBII (by conventional assay). These patients were thyrotoxic, and the diagnosis was confirmed by normal or increased radioactive iodine uptake (Table 1 ). When samples from these patients were assayed in the sensitive TBII assay with 100 g/L PEG, TBII became positive in 14 (82%) of these patients (group B in Fig. 1 ). On the other hand, none of the 16 healthy subjects showed a positive reaction even with this sensitive TBII assay (group C in Fig. 1 ). All patients with other autoimmune diseases (n ϭ 11), including rheumatoid arthritis (n ϭ 3), were also negative in the sensitive assay.
PEG, a nonionic hydrophilic polymer, has long been known to enhance the reaction rate and sensitivity of immunoassays (7 ) . PEG is also used as a promoter of cell fusion and is known to reorient membrane proteins and lipids (8 ) . In the TBII assay, PEG may have modified the three-dimensional configuration of TSHR and enhanced the binding activity of anti-TSHR antibodies.
The present study showed that the sensitive TBII assay with PEG enabled the diagnosis of patients with Graves disease whose TBII could not be detected by conventional assays. Furthermore, this sensitive TBII assay may be useful for diagnosing disease remission, especially during antithyroid drug therapy. In our previous study, one-half of the patients relapsed with thyrotoxicosis after the therapy was discontinued when TBII became negative by the conventional assay (9 ) . Similar results were also reported by other groups (2 ) . At the present time, no method is available to predict which patients will relapse. Additional study is needed to determine whether the Fig. 1 . Comparison of TBII activity in the assays with or without 100 g/L PEG in untreated patients with Graves disease and healthy subjects.
(A), patients with positive TBII (conventional assay); (B), patients with negative TBII (conventional assay); (C), healthy subjects.
sensitive TBII assay with PEG can differentiate between patients who will relapse and those who will not. Oral anticoagulants such as warfarin induce depletion of vitamin K-dependent coagulation factors, causing prolongation of the prothrombin time (PT) and the PT-International Normalized Ratio (INR). The available thromboplastins used for measuring the PT vary in their sensitivity to coagulation factor depletion, and each is assigned an International Sensitivity Index (ISI) that is used when calculating the INR. Traditional monitoring of oral anticoagulant therapy using the INR is confounded during concurrent therapy with direct thrombin inhibitors, such as argatroban, that also prolong the INR (1-3 ) . Although alternative monitoring methods have been suggested for use in this setting (2, 3 ), guidelines allowing for refined interpretation of the INR would also be useful. To facilitate the development of such guidelines, we have characterized in vitro the differential effects of warfarin and argatroban, as well as the choice of thromboplastin used, on the INR during anticoagulation with both agents.
The International Normalized Ratio during Concurrent Warfarin and Argatroban Anticoagulation: Differential Contributions of Each Agent and Effects of the
For this study, plasma specimens were obtained from 10 healthy donors (laboratory personnel) and 35 patients on warfarin therapy, in accordance with policies of the 
